Scoop has an Ethical Paywall
Scoop InfoPages
This InfoPage in unregistered, if this is your news page register PHARMAC for InfoPages here.
PHARMAC - Latest News [Page 5]
Pūahoaho: Clarity Around Pharmac’s Priority Lists
Wednesday, 9 March 2022, 9:02 am | PHARMAC
Pharmac has released up-to-date information about its priority lists, including a list of declined medicine applications as part of its ongoing commitment to transparency. “We want New Zealanders to know we have heard their concerns about a lack of transparency. ... More >>
Pharmac Proposes Widened Access To The Flu Vaccine For Māori And Pacific Peoples For 2022 Season
Tuesday, 8 March 2022, 11:22 am | PHARMAC
Pharmac is consulting on a proposal to widen access to the funded influenza vaccine to include Māori and Pacific peoples aged between 55 and 64 years of age for the 2022 influenza season. Read the consultation on widening access “We anticipate ... More >>
Pharmac Updates Access Criteria For Remdesivir
Friday, 4 March 2022, 1:56 pm | PHARMAC
Pharmac has heard from our expert advisors and clinicians treating people with COVID-19 that we need to make further changes to the temporary access criteria for remdesivir. “On Monday 28 February Pharmac temporarily widened access criteria to remdesivir ... More >>
Flu Vaccine Price Increase
Tuesday, 1 March 2022, 9:45 am | PHARMAC
Pharmac has confirmed that the purchase price of the annual influenza vaccine will increase by $2 a dose, the first increase since 2008. “The influenza vaccine has been supplied at $9 a dose for the last 14 years,” says Pharmac’s Director of ... More >>
Pharmac Ensures Earlier Access To Key COVID-19 Treatment
Monday, 28 February 2022, 2:29 pm | PHARMAC
The access criteria for remdesivir is being temporarily widened to allow hospitals to treat those with mild to moderate symptoms of COVID-19, who are at high risk of severe disease, as of today. “We initially purchased remdesivir to treat people ... More >>
Pharmac Publishes Experts’ Advice And Seeks Views On Access Criteria For COVID-19 Treatments
Wednesday, 16 February 2022, 2:41 pm | PHARMAC
Pharmac is releasing meeting records of its COVID-19 Treatments Advisory Group and seeking feedback on the patient access criteria for two COVID-19 antiviral treatments – molnupiravir (branded as Lagevrio) and nirmatrelvir with ritonavir (Paxlovid). ... More >>
Pharmac Proposing To Widen Access To Funded Medicines
Monday, 14 February 2022, 10:05 am | PHARMAC
Pharmac has issued a consultation today on proposals to widen access to two medicines, rituximab and zoledronic acid, estimated to benefit 1,750 New Zealanders a year. “Rituximab is a monoclonal antibody medicine, administered as an intravenous infusion,” ... More >>
PHARMAC Confirms Access Criteria For COVID-19 Treatments
Wednesday, 26 January 2022, 3:13 pm | PHARMAC
Pharmac has today confirmed the access criteria for two COVID-19 treatments – baricitinib and casirivimab with imdevimab (branded as Ronapreve). Both will be available for use in DHB hospitals from 1 February 2022. “Pharmac uses access criteria to ... More >>
Pharmac Publishes Experts’ Advice And Seeks Views On Patient Access Criteria For COVID-19 Treatments
Wednesday, 22 December 2021, 2:29 pm | PHARMAC
Pharmac is releasing the October meeting records of their COVID-19 clinical expert advisory group and seeking feedback on the patient access criteria for two funded COVID-19 treatments – baricitinib and casirivimab and imdevimab (branded as Ronapreve). ... More >>
Pharmac’s Year In Review
Monday, 20 December 2021, 11:07 am | PHARMAC
Today Pharmac has released its Year in Review for 2021, an annual publication highlighting key aspects of the agency’s work throughout the year. “We know New Zealanders want to learn more about our work and how we make funding decisions. We are working ... More >>
Pharmac Looking To Fund Medicines For Lung And Ovarian Cancer
Thursday, 16 December 2021, 10:54 am | PHARMAC
Pharmac is considering funding a bundle deal which would give New Zealanders more effective treatment options for lung cancer and ovarian cancer. The bundle deal also includes a new medicine for people with severe eosinophilic asthma. The bundle deal ... More >>
New Report Estimates 10,400 More Māori Should Be On Preventive Treatment For Gout
Wednesday, 8 December 2021, 12:43 pm | PHARMAC
Pharmac has today released the first of a series of reports investigating inequities in medicine access. The report looks specifically at prescribing and dispensing medicines for gout, estimating 10,400 more Māori need preventive treatment each year to achieve ... More >>
Pharmac Negotiates Deal With Pfizer For Its Promising New Oral Antiviral Treatment For COVID-19
Monday, 6 December 2021, 5:34 pm | PHARMAC
Pharmac has negotiated an agreement with the supplier Pfizer for its promising new oral antiviral treatment to treat COVID-19. “Getting vaccinated is the best defence against COVID-19. We are pleased that we have secured an additional treatment to ... More >>
Pharmac Welcomes Interim Report
Thursday, 2 December 2021, 2:08 pm | PHARMAC
Pharmac accepts many of the observations made in the Interim Report and is already making changes to how it operates. “We want to reassure New Zealanders that we are listening,” says chief executive Sarah Fitt. “The transformation of Pharmac ... More >>
Dr Jane Thomas Confirmed As Pharmac’s First Female, Māori Chair Of Expert Advisory Committee
Friday, 26 November 2021, 12:49 pm | PHARMAC
Pharmac’s Chief Executive Sarah Fitt has announced today the appointment of Dr Jane Thomas as Pharmac’s new Chair of the Pharmacology and Therapeutics Advisory Committee (PTAC). <img src="https://img.scoop.co.nz/stories/images/2111/613663b41767fbf9d03a.jpeg" ... More >>
Pharmac Widens Access To Adalimumab Through Transition To Biosimilar
Wednesday, 17 November 2021, 9:13 am | PHARMAC
Pharmac’s chief medical officer Dr David Hughes has today announced the decision to fund a biosimilar adalimumab (Amgevita), improving access to adalimumab for more than 700 New Zealanders. Adalimumab is used to treat a range of rheumatology, gastrointestinal, ... More >>
Pharmac To Fund Baricitinib To Treat Moderate To Severe Cases Of COVID-19
Friday, 5 November 2021, 10:56 am | PHARMAC
Pharmac has purchased another new medicine, baricitinib, to treat moderate to severe cases of COVID-19, with 500 courses expected in New Zealand within a matter of weeks. “Clinical trials have shown baricitinib can help hospitalised COVID-19 patients, ... More >>
Pharmac Negotiates Deal For A Further COVID-19 Treatment
Sunday, 31 October 2021, 2:06 pm | PHARMAC
Pharmac has negotiated an agreement with pharmaceutical supplier Roche to purchase another COVID-19 treatment. Branded as Ronapreve, it could be used in the prevention and treatment of COVID-19 in New Zealand. Ronapreve belongs to a class of medicines ... More >>
Cystic Fibrosis Medicine Added To Pharmac’s Options For Investment List
Wednesday, 27 October 2021, 7:15 am | PHARMAC
Pharmac has announced that Vertex’s triple combination modulator therapy, known in some countries as Trikafta, has been added to the priority list of medicines it would like to fund. In July this year, pharmaceutical company Vertex applied to Pharmac ... More >>
Pharmac Negotiates Deal For Molnupiravir To Treat COVID-19
Monday, 11 October 2021, 6:17 am | PHARMAC
Pharmac has negotiated an agreement with supplier Merck Sharp & Dohme (MSD) to purchase the antiviral molnupiravir. It will be used to treat New Zealanders with mild to moderate COVID-19 symptoms, subject to the treatment gaining regulatory approval ... More >>
